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http://www.retrovirology.com/content/10/1/2RESEARCH Open AccessN-terminal Slit2 inhibits HIV-1 replication by
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Background: Slit2 is a ~ 200 kDa secreted glycoprotein that has been recently shown to regulate immune
functions. However, not much is known about its role in HIV (human immunodeficiency virus)-1 pathogenesis.
Results: In the present study, we have shown that the N-terminal fragment of Slit2 (Slit2N) (~120 kDa) inhibits
replication of both CXCR4 and CCR5-tropic HIV-1 viruses in T-cell lines and peripheral blood T-cells. Furthermore,
we demonstrated inhibition of HIV-1 infection in resting CD4+ T-cells. In addition, we showed that Slit2N blocks
cell-to-cell transmission of HIV-1. We have shown that Slit2N inhibits HIV-1 infection by blocking viral entry into
T-cells. We also ruled out Slit2N-mediated inhibition of various other steps in the life cycle including binding,
integration and viral transcription. Elucidation of the molecular mechanism revealed that Slit2N mediates its
functional effects by binding to Robo1 receptor. Furthermore, we found that Slit2N inhibited Gp120-induced
Robo1-actin association suggesting that Slit2N may inhibit cytoskeletal rearrangements facilitating HIV-1 entry.
Studies into the mechanism of inhibition of HIV-1 revealed that Slit2N abrogated HIV-1 envelope-induced actin
cytoskeletal dynamics in both T-cell lines and primary T-cells. We further showed that Slit2N specifically attenuated
the HIV-1 envelope-induced signaling pathway consisting of Rac1, LIMK and cofilin that regulates actin
polymerization.
Conclusions: Taken together, our results show that Slit2N inhibits HIV-1 replication through novel mechanisms
involving modulation of cytoskeletal dynamics. Our study, thus, provides insights into the role of Slit2N in HIV-1
infection and underscores its potential in limiting viral replication in T-cells.Background
Slits belong to a group of large secretory glycoproteins
that were initially described as regulating axonal guid-
ance during the development of the central nervous sys-
tem [1,2]. Slit consists of a family of three genes: Slit1,
Slit2 and Slit3 that are highly homologous to each other
and encode ligands for the Roundabout (Robo) receptors
[3,4]. It is now clear that Slit and Robo genes are
expressed in a range of tissues in addition to the brain,
where Slit-Robo signaling has critical functions [5].
However, information on the effects of Slit2 in non-
neuronal systems is not well-studied, with recent studies
indicating that Slit2/Robo1 complex regulates lung and
kidney development, tumor angiogenesis and metastasis* Correspondence: Ramesh.Ganju@osumc.edu
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reproduction in any medium, provided the or[6-11]. With regard to the immune system, Slit2 has
been shown to inhibit migration of hematopoietic cells,
monocytes, neutrophils, dendritic cells, and T lympho-
cytes, toward chemoattractant signals [12-15]. Specific-
ally, we and others have shown Slit2 blocks CXCL12/
CXCR4-mediated chemotaxis in T-cells [15,16]. In
addition, we recently showed that full-length Slit2 inhibited
both X4 and R5-tropic HIV-1 replication in T-cells [17].
Recently, Slit2N also was shown to regulate HIV-1-gp120-
induced endothelial permeability [18].
A prototypical Slit2 protein contains an N-terminal
signal peptide, four leucine-rich repeats (LRRs), seven
(in Drosophila Slit) or nine (in vertebrate Slits) EGF
repeats, and a C-terminal cysteine knot [19]. Studies
have shown that full-length Slit2 is cleaved between the
fifth and sixth EGF-like repeat into a 120–140 kDa N-
terminal and a 50–60 kDa C-terminal fragment [20].
Recent evidence suggests that the N-terminal region ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of Slit2 [5,21].
The intracellular signal transduction mechanism for
Slit2/Robo1 signaling is not well-studied. However, sev-
eral lines of recent evidence have demonstrated that
Slit2 regulates actin polymerization after binding to
Robo receptor [16,22-24]. Robo is a transmembrane re-
ceptor that consists of a fibronectin type III and im-
munoglobulin (Ig)-like domains and an intracellular
cytoplasmatic domain. The intracellular domain of Robo
has been shown to interact with proteins that regulate
the Rho family of small guanosine triphosphates
(GTPases), which play well-defined roles in cell migra-
tion, cytoskeletal organization and remodeling by elicit-
ing changes in actin cytoskeleton [25]. Furthermore,
HIV has the capacity to bind to its receptors, CD4 and/
or co-receptors (CXCR4 or CCR5) and induce signal
transduction pathways that trigger actin cytoskeletal
rearrangements facilitating viral entry [26-30].
In the present study, we have analyzed the effect of N-
terminal domain of Slit2 (Slit2N) in HIV-1 infection and
shown that it inhibits replication of both X4 and R5-
tropic HIV-1. Furthermore, our mechanistic studies in
T-cell lines and primary T-cells have revealed that Slit2
inhibits the HIV-1 viral entry through a novel mechan-
ism involving modulation of actin cytoskeletal dynamics.
Results
N-terminal fragment of Slit2 mediates anti-HIV-1 activity
Slit2 contains the N-terminal region consisting of four
leucine-rich repeats (LRRs), nine epidermal growth fac-
tor (EGF) repeats, a laminin G domain, and a C-
terminal cysteine-rich region (Figure 1A) [19]. Studies
have shown that full-length Slit2 is cleaved between the
fifth and sixth EGF-like repeat into a 120–140 kDa N-
terminal and a 50–60 kDa C-terminal fragment, and the
biological effects of Slit2 are mediated by the N-terminal
fragment [20]. In the present study, we first analyzed the
anti-HIV-1 activity of a purified Slit2N fragment.
Firstly, the purity of Slit2N was determined by silver
staining (Figure 1B). To confirm that Slit2N does not
affect the viability and proliferation of T-cells, we per-
formed the MTT assay (Roche, Indianapolis, IN) as per
the manufacturer’s recommendations, using various con-
centrations of Slit2N. We found that Slit2 did not affect
cell viability or cell proliferation (data not shown). We
also demonstrated that Slit2 did not affect T-cell activa-
tion (data not shown). Next, we evaluated the anti-HIV-
1 activity of Slit2N against cell-free virus. We used a
range of concentrations of Slit2N (0.6-60 nM), and
Slit2N clearly showed a dose-dependent inhibition of
HIV-1 replication in MT4 cells (Figure 1C). We obtained
a maximum inhibition of 82.6% when Slit2N was used at
a concentration of 60 nM.To check the specificity of activity of Slit2N against
HIV-1, we pre-incubated MT4 cells with or without
Slit2N and then infected these cells with HIV-luc pseu-
dotyped with the VSV-G envelope protein. This single-
life cycle virus does not require HIV receptors to enter
the target cells [31]. Incubation of MT4 cells with Slit2N
had no effect on infection with HIV-Luc pseudotyped
with VSV-G (Figure 1D).
Several recent studies have indicated that the func-
tional effects of Slit2 are concentrated in the D2 do-
main of Slit2 [4,32]. To verify whether the D2 region
is responsible for the anti-HIV activity of Slit2, we
obtained a mutant Slit2 protein that lacks the second
leucine-rich region that is necessary for binding to
Robo1 (Slit2ΔD2) [33]. MT4 cells were infected with
HIV-1 IIIB in the presence of equivalent concentra-
tions of Slit2N and Slit2 ΔD2 (≈6nM). We found that
Slit2 ΔD2 showed no inhibition of HIV replication in
comparison to Slit2N (Figure 1E), indicating that the
anti-HIV activity of Slit2 is restricted to the D2 domain of
Slit2.
In addition to infection with cell-free virions, the
importance of cell-associated spread across connect-
ing membrane bridges and close cell–cell contacts is
increasingly recognized and thought to constitute the
predominant mechanism of HIV-1 propagation in vivo
[34,35]. We, therefore, examined whether Slit2N has an
effect on cell-cell transmission of HIV-1. Briefly, MT4
cells were first productively infected with HIV-1 IIIB.
After 24 hours, ~70-80% of the cells were HIV-1 p24
positive by intracellular p24 staining and flow cytome-
try (data not shown). These cells were used as donors
and co-cultivated with Far-red Cell trace dye-labeled
Jurkat T-cells in the presence of various concentrations
of Slit2N, as described in the Methods. As shown in
Figure 1F, we clearly observed a dose-dependent inhib-
ition of HIV infection in the target cells with max-
imum inhibition of 62.5% when Slit2N was used at
60nM. These studies indicate that Slit2N also inhibits
cell to cell spread of HIV in T-cells.
We further evaluated the effect of Slit2N on HIV-1
IIIB (X4) and BaL (R5) replication in PHA-
stimulated CD4+ T-cells. We observed an approxi-
mately 40% reduction in HIV-1 replication with both
X4-tropic virus and R5-tropic virus (Figure 2A, left
and right panel), indicating that Slit2N inhibits HIV-
1 replication irrespective of the co-receptor used by
the virus. We also tested the effect of Slit2N on in-
fection of resting CD4+ T-cells. Cells pre-treated
with Slit2N and infected with HIV-1 IIIB were incu-
bated for 5 days, after which they were activated
with anti-CD3/CD28 beads to initiate viral replica-
tion (Figure 2B, upper panel). Supernatants collected
at various time points after activation were examined
Figure 1 The N-terminal Slit2 fragment possesses anti-HIV-1 activity. (A) Domain organization of Slit2 showing LRR, leucine-rich repeat; EGF,
epidermal growth factor-like; LG, laminin G-like; CT, C-terminal cystine regions. (B) Silver staining of the Slit2N protein. (C) MT4 cells pre-treated
with various concentrations of Slit2N were infected with HIV-1 IIIB (10 ng p24). We used heat-inactivated (H.I) Slit2N as a control. After 48 hours,
supernatants were collected for estimation of HIV-1 p24 antigen levels by ELISA. Virus production in the positive control (control HIV-1 infected
MT4 cells): 4.8 ng/ml p24 Ag. Heat-inactivated Slit2N at a concentration of 60nM was used as a control. (D) MT4 cells were treated with Slit2-N
(6 nM) for 30 minutes and then infected with HIV-Luc viruses pseudotyped with VSV-G envelope (VSV-G) for 2 hours. Forty-eight hours post
infection, cells were harvested for the Luciferase assay. (E) MT4 cells were treated with equivalent concentrations of Slit2N and Slit2 ΔD2 (≈6nM)
and infected with HIV-1 IIIB (10 ng p24) for 48 hours. Virus production in the supernatants was estimated by HIV-1 p24 ELISA. (F) MT4 cells
infected with HIV-1 IIIB were co-cultured with dye-labeled target Jurkat T-cells in the presence of various concentrations of Slit2N for 4 hours, and
the percentage of Gag+ target cells was measured by flow cytometry. The results are represented in a bar graph. Values are the mean
percentages of Gag+ dye-labeled target cells with the SEMs. Infected cells were used when >70-80% of the donor cells were routinely Gag+ by
flow cytometry. Data are representative of three independent experiments. *P ≤ 0.05 versus untreated cells.
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Figure 2 Slit2N inhibits HIV infection of activated and resting CD4+ T-cells. (A) PHA-stimulated CD4+ T-cells were infected with HIV-1 IIIB
(left panel) or HIV-1 BaL (right panel) in the presence of Slit2N (3nM). The cells were incubated in IL-2 containing medium, and the cells were
collected after 48 hours and analyzed for HIV-1 p24 expression by flow cytometry. *P < 0.05 versus untreated cells infected with HIV-1. (B) Resting
CD4+ T-cells were infected with HIV-1 IIIB in the presence or absence of Slit2N (3nM). Following infection, the cells were washed to remove
unbound virus and cultured in the presence of Slit2N for 5 days. Cells were activated at day 5 with anti-CD3/CD28 magnetic beads, and viral
replication was measured by p24 release. Results are representative of 3 separate experiments.
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nificant reduction in HIV infection (approximately
65%) in resting CD4+ T-cells (Figure 2B, lower
panel).
Slit2 attenuates viral entry
In order to determine how Slit2N-mediated inhibition
works, we first determined the step in the HIV-1 life
cycle that was inhibited by Slit2N. Time of addition
assays pointed to the inhibition of early pre-integrative
steps in the viral life cycle (data not shown). Our next
objective was to further determine the exact pre-
integrative step in the viral life cycle that is inhibited by
Slit2N. The first step in the viral life cycle is the bindingof the virus onto the receptors on the T-cells. Therefore,
we first determined whether HIV-1 receptor expression
was affected by Slit2N. Treatment of cells with Slit2N
did not affect membrane expression of CD4, CXCR4 or
CCR5, which are required for HIV-1 binding and entry
into cells (Figure 3A). To investigate whether Slit2N is
capable of inhibiting the binding of HIV-1 gp120 to its
receptors on T-cells, we analyzed the binding ability of
FITC-conjugated recombinant gp120 to the Slit2N-
treated and untreated MT4 cells. As shown in Figure 3B,
Slit2N did not affect the binding of gp120 to T-cells. We
also determined the binding of HIV-1 virus to MT4 cells
using the virus binding assay. As shown in Figure 3C,
though there was no difference in the binding of HIV-1
Figure 3 Slit2N blocks HIV-1 entry, but does not affect HIV-1 receptor expression, envelope binding or HIV-1 virus binding to T-cells.
(A) To analyze the effect of Slit2N on HIV-1 receptor expression, MT4 cells or PBMCs were treated with Slit2N for various time periods. MT4 cells
were analyzed for CD4 and CXCR4 expression while PBMCs were analyzed for CCR5 expression, respectively, by flow cytometry. (B) MT4-cells
were treated with Slit2N and analyzed for Gp120 binding by flow cytometry using FITC-tagged gp120. (C) For virus binding, untreated and Slit2N
(3 nM and 6 nM) -treated MT4 cells were infected with HIV-1 IIIB (40 ng/106 cells) and incubated for one hour at 4°C, and the cell lysates were
analyzed for HIV-1 p24 levels. (D) MT4 cells infected with HIV-1 IIIB were incubated for 3 hours at 37 ° C in the presence or absence of Slit2N
(3nM and 6nM). The cells were treated with trypsin, washed, lysed and analyzed for intracellular p24 antigen levels by ELISA. *P < 0.05 versus the
control preparation. (E) Untreated and Slit2N-treated MT4 cells were incubated with BlaM-Vpr-containing virions (500 ng of p24), after which the
cells were washed and incubated with CCF2-AM loading mix (GeneBLAzer detection kit; Invitrogen). The excess dye was washed off and cells
were incubated for 16 h at room temperature before fixation with 4% paraformaldehyde. The entry of Blam-Vpr containing virions was measured
as the ratio of the maximum fluorescence intensity between cleaved and intact CCF2. *P < 0.05 versus the control infected cells. Results are
representative of 3 separate experiments.
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the binding of virus to the receptors on T-cells was not
affected by Slit2N.
Next, we further specifically tested the ability of Slit2N
to block cellular entry of HIV-1 in MT4 cells using aFigure 4 Slit2N does not affect HIV-1 integration or transcription. (A)
hours after infection (to bypass the entry step). Twenty-four hours after infe
integrated HIV-1 DNA was analyzed by qPCR for Alu-LTR. (B) The full length
Uninfected and HIV-1 infected MT4 cells were used as controls. Results areHIV-1 virus entry assay. We observed a significant re-
duction (~40%) in the amount of virus that enters the
cell in Slit2N-treated cells as compared to the control
(Figure 3D). To further analyze the role of Slit2N in
inhibiting HIV-1 infection, we performed viral fusionMT4 cells were treated with Slit2N prior to HIV-1 infection or three
ction, DNA was extracted from the respective samples, and the
and spliced (C) RNA transcription was evaluated by qRT-PCR.
representative of 3 separate experiments.
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particles containing the BlaM-Vpr chimera [36]. These
chimera virions have been designed to specifically study
the first steps of viral infection, since β-lactamase activ-
ity directly correlates with viral entry. Untreated and
Slit2N-treated MT4 cells were incubated (3 h) with
equivalent viral inputs of X4-tropic virions containing
BlaM-Vpr fusion protein. Untreated cells were suscep-
tible to viral entry, whereas in cells treated with Slit2N,
viral entry was strongly reduced (~50%) (Figure 3E).
Taken together, these data indicate that Slit2N inhibits
HIV-1 viral fusion and entry.Figure 5 Slit2N mediates HIV-1 inhibition by binding to the Robo1 re
siRNA by nucleofection (Amaxa biosystems) were analyzed for Robo1 ex
(B) The NT and Robo1 siRNA-transfected cells were pre-treated with Slit2
for 48 hours. The supernatants were analyzed for HIV-1 p24 levels by ELI
(C) MT4 cells were stimulated with HIV-1 gp120 for various periods of time in
immunoprecipitated (IP) with anti-Robo1 antibody. The immune complexes w
reprobed with Robo1 antibody. TCL- total cell lysate. IgG- antibody control. ReWe further evaluated the effect of Slit2N on integra-
tion and post-integrative steps including transcription.
In one set of samples, we pre-treated MT4 cells with
Slit2N prior to infection with HIV-1-IIIB. In another set
of samples, we treated the infected cells with Slit2N,
3 hours after infection to bypass the entry step. After
twenty-four hours, proviral HIV-1 DNA was measured
with qPCR assays toward LTR-Alu sequences (LTR-Alu)
as previously described [37], to measure virus integra-
tion. We also quantitated the number of full-length and
spliced viral transcripts in the infected cells by qRT-
PCR. We did not detect a significant difference in virusceptor. (A) MT4 cells transfected with non-targeting (NT) or Robo-
pression by Western blotting. GAPDH was used as a loading control.
N (3nM) or control, and left uninfected or infected with HIV-1 IIIB
SA. *P < 0.05 versus the mock-infected cells transfected with NT-siRNA.
the presence and absence of Slit2N. The lysates were
ere then immunoblotted with β-actin antibody. The same blot was
sults are representative of 3 separate experiments.
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spliced mRNA levels (Figure 4C) between HIV-1
infected untreated MT4 cells and Slit2 -treated MT4
cells, when Slit2N was added after HIV-1 entry step.
However, when Slit2N was added before infection of theFigure 6 Slit2N inhibits HIV-1-envelope-mediated actin polymerizatio
gp120 for various time points, as indicated. Cells were taken at various tim
cytometry. The graph represents the percentage increase in F-actin positive
also observed under a fluorescence microscope. The images shown are ce
treated with Slit2N (3nM) and treated with gp120 for various time points, a
FITC-phalloidin and quantified by flow cytometry. The graph represents the
cells stained with phalloidin-FITC were also observed under a fluorescence
5 minutes.cells, Slit2N-treated cells showed a significant difference
in the both viral integration and transcription. These
results suggest that Slit2N does not regulate HIV-1 inte-
gration or transcription in T-cells, but inhibits steps
prior to integration.n. (A) MT4 cells were pre-treated with Slit2N (3nM) and treated with
e points and stained with FITC-phalloidin and quantified by flow
cells over the control. (B) The cells stained with phalloidin-FITC were
lls stimulated with Gp120 for 5 minutes. (C) Resting T-cells were pre-
s indicated. Cells were taken at various time points and stained with
percentage increase in F-actin positive cells over the control. (D) The
microscope. The images shown are cells stimulated with Gp120 for
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Our next aim was to decipher the molecular mechanism
by which Slit2N mediates HIV-1 inhibition. Robo1 is a
protein with a single transmembrane domain, serving as
a Slit2 receptor in various cells and mediates a majority
of Slit2N-mediated effects. We, therefore, assessed the
role of Robo1 in Slit2N-mediated inhibition of HIV-1 in-
fection. MT4 cells transfected with Robo1 siRNA
showed a significant knock-down of Robo1 expression
as compared to cells transfected with non-targeting
siRNA (Figure 5A). The transfected cells were infected
with HIV-1 IIIB and observed for HIV-1 p24 levels after
48 hours of incubation. As shown in Figure 5B, Robo1
downregulation abrogated Slit2-mediated inhibitory
effects compared to control, suggesting that the anti-
HIV-1 activity of Slit2N is predominantly transduced by
the Robo1 receptor.
Slit2 inhibits the HIV-1-envelope induced Robo1-actin
association
Since studies have shown that Robo associates with several
actin-related proteins to mediate its functions [38-40], we
evaluated whether HIV-1 gp120 regulates the association of
Robo1 with actin. Interestingly, we found that treatment
with HIV-1 gp120 enhanced the association of the Robo1
receptor with actin. However, pretreatment with Slit2N
attenuated the gp120-induced Robo1-actin association at 5,
15 and 30 minute intervals (Figure 5C), indicating that
Slit2N upon binding to Robo1 inhibits Robo1/actin associ-
ation and may thus modulate HIV-1-induced cytoskeletal
changes facilitating viral entry.
Slit2N attenuates HIV-1-envelope-induced actin
polymerization in T-cells
We further investigated the signaling mechanisms of
Slit2N-mediated inhibition of viral entry. In HIV-1 infec-
tion, binding of the virus to CD4+ T cells initiates an early
actin polymerization in T-cells [29,41] followed by
depolymerization [29], a process mimicking the chemotac-
tic response initiated from chemokine receptors. The actin
polymerization has been suggested to promote viral entry
[28-30]. To determine whether Slit2N affects HIV-1-
induced cytoskeletal changes, MT4 cells were untreated or
treated with Slit2N and stimulated with HIV-1 gp120, fixed
and stained for F-actin. As expected, gp120 induced actin
polymerization at early time points (15 and 30 minutes).
However, in the presence of Slit2N, gp120-induced actin
polymerization was significantly inhibited, as demonstrated
by flow cytometry (Figure 6A). We also observed a signifi-
cant inhibition of gp120-induced actin polymerization
by Slit2N by fluorescence microscopy (15 minutes)
(Figure 6B).
To determine whether Slit2N affects HIV-mediated
actin dynamics leading to virus entry in primary cells,we examined the effect of Slit2N on HIV-1 envelope-
mediated actin dynamics in resting CD4+ T-cells.
Actin polymerization was demonstrated by changes in
phalloidin-FITC binding to F-actin over time. We
found that HIV gp120 transiently triggered low actin
polymerization at early time points in primary T-cells.
Pre-treatment with Slit2N inhibited early actin
polymerization in these cells (Figure 6C and D), indi-
cating that Slit2 may inhibit HIV-1 entry by modulat-
ing the cytoskeletal changes induced by HIV-1.
Slit2 inhibits signaling mechanisms that regulate Gp120-
induced actin cytoskeletal dynamics
We further evaluated the mechanism by which Slit2N
inhibits HIV-1 gp120-induced actin polymerization. The
mechanism that triggers early actin polymerization
through HIV-1 envelope-mediated transient activation of
the Rho GTPase, Rac1 and the LIM domain kinase
(LIMK), has recently been described [27-29,42,43].
LIMK1 is a protein that phosphorylates and inactivates
cofilin that in turn enhances actin polymerization thus
facilitating HIV entry. We therefore hypothesized that
Slit2N may decrease early actin polymerization by pre-
venting HIV-envelope-induced activation of the Rac1/
LIMK1/cofilin pathway.
We first tested the effects of Slit2N on HIV-1-enve-
lope-induced Rac1 activation in T-cells. We used agarose
beads conjugated to the PBD of PAK (PAK-PBD) to de-
tect the activated, GTP-bound species of Rac1. Unstimu-
lated T-cells had low basal levels of activated Rac1.
Exposure to gp120 increased levels of activated Rac1.
Slit2N did not affect basal levels of activated Rac1 (data
not shown), but inhibited gp120-induced activation of
Rac1 significantly (Figure 7A). Furthermore, we found
that Slit2N inhibited Gp120-induced phosphorylation of
both LIMK1 (Figure 7B) as well as phosphorylation of
cofilin (Figure 7C).
We also showed that treatment of resting CD4+ T-
cells with Slit2N also interfered with HIV-envelope
induced phosphorylation of LIMK1 and cofilin. (Figure 7
D and E). Together, these results suggest that Slit2N
inhibits Gp120-induced Rac1/LIMK1/cofilin pathway
that mediates actin polymerization, thereby blocking
HIV-1 entry.
Discussion
A prototypical Slit2 protein contains an N-terminal sig-
nal peptide, four leucine-rich repeats (LRRs), seven
(in Drosophila Slit) or nine (in vertebrate Slits) EGF
repeats, and a C-terminal cysteine knot [44]. Structural-
functional analysis of Slit2 has revealed that the anti-
HIV-1 activity of Slit2 was present in the N-terminal do-
main of Slit2. In the present study, we also showed that
the N-terminal region of Slit2 was sufficient to mediate
Figure 7 Slit2N attenuates HIV-1 envelope-induced signaling pathway that mediates actin cytoskeletal reorganization. (A) Lysates from
untreated, full-length Slit2 and Slit2N (3nM)-treated MT4 cells were stimulated with X4-tropic HIV-1 gp120 (10nM) for 10 minutes. The lysates were
pre-cleared with sepharose beads and incubated with 20 μg/ml p21-activated kinase (PAK)-1 agarose for 60 minutes at 4°C. Agarose beads were
collected by centrifugation and analyzed for Rac1-binding activity by Western blotting with anti-human Rac1 antibody (upper panel). Lysates
probed with total Rac1 (lower panel) represent loading controls. (B) MT4 cells, pretreated with Slit2N, were treated with HIV-1 gp120 for various
time points and lysed. To demonstrate LIMK1 activation, the lysates were immunoblotted for phospho-LIMK1. The blots reprobed with total
LIMK1 antibody represented loading controls. (C) The same lysates were also immunoblotted with phospho-cofilin. Probing for total cofilin
represented the loading control. (D) Resting primary T-cells, pretreated with Slit2N were treated with HIV-1 gp120 for various time points and
lysed. To demonstrate LIMK1 activation, the lysates were immunoblotted for phospho-LIMK1. The blots reprobed with total LIMK1 antibody
represented loading controls. (E) The same lysates were also immunoblotted with phospho-cofilin. Probing for total cofilin represented the
loading control. All of the above experiments were repeated three times, and a representative experiment is shown.
Anand et al. Retrovirology 2013, 10:2 Page 10 of 16
http://www.retrovirology.com/content/10/1/2anti-HIV-1 activity in T-cells. A recent study has also
evaluated the administration of Slit2N in a murine
model of H5N1 influenza [21]. Furthermore, Slit2N also
attenuated HIV-1 gp120-induced endothelial permeabil-
ity [18]. Our findings are thus in agreement with recentstudies that indicate that many of the biological func-
tions of Slit2 are mediated by the N-terminal fragment
[5,21].
In the present study, we showed that Slit2 not only
inhibited infection of T-cells with cell-free virus, but also
Figure 8 Proposed mechanism of Slit2N-mediated inhibition of
HIV-1 entry. Slit2N inhibits HIV-1 envelope-induced Rac1/LIMK1/
cofilin pathway, thus attenuating actin polymerization, ultimately
blocking virus entry. Furthermore, Slit2N also inhibits HIV-1
envelope-induced Robo1/actin association, possibly modulating
cytoskeletal rearrangements that facilitate HIV-1 entry.
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of HIV-1–infected and noninfected cells. Cell-cell trans-
mission of HIV-1, through the formation of a virological
synapse, is the predominant mode of HIV-1 transfer
in vivo and probably occurs in secondary lymphoid
organs, where most lymphocytes are present and cells
are in close contact with each other and with antigen-
presenting cells [34,35].
The initial steps in the HIV-1 viral life cycle include
the binding of the viral envelope glycoproteins to the
primary receptor, CD4 and co-receptors, CXCR4/CCR5
followed by membrane fusion and viral entry. Recently,
Slit2 was shown to downregulate CXCR4 expression in
breast cancer cells [8]. However, in contrast to breast
cancer cells, Slit2N did not have any effect on the down-
regulation of either CXCR4/CCR5 or CD4 expression,
ruling out down-modulation of HIV-1 receptors/co-
receptors as a mechanism of action for Slit2. In addition,
virus binding assays indicated that Slit2N did not inhibit
HIV-1 binding onto target cells. However, specific entry
assays demonstrated that Slit2 inhibited viral entry into
the target cell.
In our mechanistic studies, we showed the importance of
Robo1 in Slit2-mediated inhibition of HIV-1 replication
using siRNA-mediated Robo1 knockdown experiments.
This is in agreement with various genetic and biochemical
experiments that have shown that Slit2 binds to Robo1 re-
ceptor to mediate signaling and many of its functional
effects [1,3,4,15,16,23]. Our next aim was to investigate the
exact mechanism of inhibition of virus entry. The early
interaction between HIV and T cells initiates intracellular
signaling cascades that are important for the early steps of
the HIV life cycle [28,45].
The cortical actin is a common structure that is targeted
by most viruses for entry and intracellular transport [46,47].
In HIV-1 infection, the direct involvement of the cortical
actin in early stages of viral infection has been suggested in
HIV-mediated CD4-CXCR4 receptor clustering [26,46,48],
and intracellular migration [28]. Actin polymerization has
been shown to promote viral entry in both the simple
model of infection by free virus and the more physiologic-
ally relevant route of infection through the virological
synapse [26,28-30,45,49]. In this study, we showed that
Slit2N inhibits gp120-induced actin polymerization
and Robo-actin association at early time points. This is
in agreement with the common theme emerging from
a number of studies that Slit2 mediates cellular guid-
ance through regulation of actin polymerization as well
as data from neuronal cells linking Robo to proteins
associated with the actin cytoskeleton including ena
and srGAP1 [11, 14, 22, 23, 50].
The data implicating that Slit2N inhibits Gp120-
induced actin polymerization led us to evaluate the
intracellular molecules that transduce the signal toregulate the actin polymerization. Several studies indi-
cate that the regulatory effect of Slit2 involve modula-
tion of Rho family of small GTPases, Rac1 and cdc42
[11,14,23,50]. Rho-GTPases play a definitive role in cell
migration, cytoskeletal organization and actin remodel-
ing. A recent study has also shown that the binding of
HIV-1 envelope glycoprotein with the primary receptor
CD4 and one of the co-receptors, CXCR4 or CCR5 acti-
vates a signaling cascade resulting in activation of Rho
GTPases, specifically Rac1 and actin cytoskeletal remod-
eling that facilitate HIV-1-induced membrane fusion and
virus entry [27]. Rac1 has been shown to be activated by
gp120 to trigger actin polymerization to mediate both
cell-cell [49] and virus-cell fusion [27]. Furthermore, an-
other recent study has described a pathogenic mechan-
ism for triggering early actin polymerization through
HIV-1 envelope-mediated transient activation of Rac1-
LIMK1-cofilin pathway [29].
The LIM domain kinase, LIMK, is a protein that phos-
phorylates cofilin and LIMK1-mediated actin polymerization
was shown to directly facilitate early CD4 CXCR4 clustering
and viral entry. These studies led us to test the effects of
Slit2N on the HIV-1-envelope-induced activation of LIMK1
and cofilin. We found that Gp120-induced phosphorylation
of LIMK1 and cofilin was inhibited by Slit2N. Previously, it
has been shown that early LIMK1 activation in response to
HIV envelope occurs in both unstimulated and stimulated
T-cells [29]. Furthermore, the authors also showed LIMK
activation upon infection of human primary macrophages
with the CCR5-utilizing viruses [29]. These findings indicate
that the Rac1/LIMK1/cofilin pathway leading to early actin
polymerization is rather a general mechanism occurring
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mary resting/active CD4 T cells and macrophages. Based on
our results, we hypothesize that Slit2N blocks HIV-1
induced activation of Rac1/LIMK1/cofilin pathway that
leads to actin polymerization, thus blocking HIV-1 entry
(Figure 8).
Conclusion
In summary, our studies reveal that N-terminal region
of Slit2 possesses anti-HIV-1 activity against both X4
and R5-tropic viruses. Furthermore, elucidation of the
signaling mechanisms revealed that Slit2N regulates
HIV-1 infection by inhibiting HIV entry into target cells
through modulation of cytoskeletal dynamics. We have
shown that Slit2N inhibits gp120-induced Robo1-actin
association. In addition, our studies revealed that Slit2/
Robo1 modulates cytoskeleton by attenuating Rac/
LIMK1/cofilin pathway. Our findings thus elucidate the
role of Slit2N in HIV-1 infection and could provide
insights into novel approaches to limit HIV-1 infection.
Methods
Viral isolates
The lab-adapted X4-tropic virus, HIV-1 IIIB and the R5-
tropic virus, HIV-1 BaL, used in this study were
obtained from the NIH AIDS Research and Reference
Reagent Program.
Anti-HIV-1 assays
MT4 cells, a human T-cell line bearing human T-cell
leukemia virus type 1 (NIH AIDS Research and Refer-
ence Reagent program) were grown in RPMI 1640
medium (Mediatech, Manassas, VA) supplemented with
10% heat-inactivated fetal calf serum (FCS) (Invitrogen,
Carlsbad, CA) and antibiotics. Peripheral blood mono-
nuclear cells (PBMCs) were isolated from heparinized
venous blood collected from healthy HIV-1-seronegative
donors (American Red cross, Columbus, OH) by Ficoll-
Paque density gradient centrifugation (GE Biosciences,
Piscataway, NJ). The study was done in compliance with
the Helsinki declaration on rights of human subjects
with approval from the Ohio State University Institu-
tional Review Board (2007H0281). Monocytes were
depleted by two rounds of adherence to plastic. Nonad-
herent cells were either rested overnight in complete
RPMI and used for infection or stimulated with phyto-
hemagglutinin (PHA) (5 μg/ml) for 3 days. CD4+ T-cells
were isolated according to the manufacturer’s protocol
by immunomagnetic selection (EasySep Kit, Stem Cell
Technologies, Canada).
MT4 cells pre-treated with various concentrations of
Slit2N (0.6-60 nM) were infected with HIV-1 at 10 ng
p24/106 cells. The cells were washed extensively after
two hours of infection to remove the unbound virus andincubated for 48 hours. PHA-stimulated PBMCs were
pre-treated with Slit2N and infected similarly with HIV-
1. The culture supernatant were assessed with the HIV-1
p24 ELISA (Advanced Bioscience Laboratories, Kensing-
ton, MD).
For infection of resting CD4+ T-cells, HIV-1 IIIB
(10 ng p24) was used to infect 106 cells. For these stud-
ies, T-cells were pretreated with Slit2N (6nM), incubated
with the virus for 2 hours at 37°C and washed twice with
medium to remove the unbound virus. Infected cells
were resuspended into fresh complete RPMI containing
Slit2N (6nM) at a density of 106/ml and incubated for
5 days without stimulation. Cells were activated at day 5
with anti-CD3/CD28 magnetic beads (Dynal) at 2–4
beads per cell to initiate viral replication. Infected cells
were pelleted at various time points and supernatants
used for p24 ELISA.Quantification of cell-cell spread by flow cytometry
To measure cell-cell spread by flow cytometry, an adap-
tation of the assay of Sourisseau et al. [51] was used.
Briefly, an equal number of HIV-1-infected donor MT4
cells were mixed with CellTrace Far Red-labeled target
T cells (2 μM; Invitrogen) in the presence of various
concentrations of Slit2N (0–60 nM) and incubated for
4 h at 37°C. In addition, infected cells were treated with
trypsin-EDTA prior to fixing to further diminish doublet
formation and to remove surface-absorbed p24. Cells
were then fixed in 4% formaldehyde, washed, and per-
meabilized in BD Perm/Wash buffer (BD Biosciences),
and HIV-1 p24 was detected with the FITC-conjugated
HIV p24 antibody (Pierce) and data acquired using a
FACSCalibur (BD Biosciences). The percentage of HIV-
p24+ cells among the CellTrace FarRed-labeled target
cells was quantified and data analysis performed using
CellQuest 5.0.Proteins antibodies and plasmids
Slit2N protein was obtained either from AbCam
(Cambridge, MA) or Creative Biomart (Shirley, NY);
LIMK1, Cofilin and GAPDH antibody was obtained
from Cell signaling (Danvers, MA), while Robo1
antibodies were obtained from AbCam. Slit ΔD2 was
prepared by transfecting the Slit ΔD2 plasmid in
293 T cells. The protein was purified from the
supernatants as described before [16]. The Slit ΔD2
plasmid was cloned in pTT28 by deleting the second
LRR domain of truncted Slit2 (Slit2-N) using restric-
tion enzymes BsrGI and NheI. After deleting 210
amino acids (Q235-W444) of Slit2-N, a short synthe-
sized linker corresponding to amino acids YTAGG-
SAGGSAGGSAGKL was inserted into BsrGI and
NheI restriction sites [33].
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HIV-1 viruses pseudotyped with vesicular stomatitis
virus envelope protein (VSV-G) were prepared as previ-
ously described [52,53]. Briefly, 293 T cells (27 × 106 per
10 cm plate) were transfected with 20 μg of pNL4-3.Luc.
R-E- (HIV-Luc) plasmid and 4 μg of pVSV-G (obtained
from the NIH AIDS Research and Reference reagent
program) by lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer’s instructions. Cell cul-
ture supernatants were collected 48 hours later, filtered
and saved as virus stocks. For infection, pseudotyped
viruses corresponding to 10 ng p24 were used to infect
target cells. Following 2 hour infection, the cells were
washed extensively to remove unbound viruses. The
cells were incubated for 48 hours and harvested for luci-
ferase activity as previously described [53].
Immunostaining and flow cytometry
FITC- or PE-labeled monoclonal antibodies against
human CD4, CCR5 or CXCR4 were purchased from BD
Biosciences. Half million cells were incubated with iso-
type control or the labeled antibodies on ice in PBS-
0.1%BSA for 30 minutes. Cells were washed with cold
PBS-0.5% BSA, and then analyzed on a FACSCalibur
(BD Biosciences). To determine intracellular p24, HIV-1
infected T- cells were fixed and permeabilized using
Fix/perm solution (BD Biosciences, San Jose, CA) and
stained with KC57 monoclonal antibody (Coulter, Brea,
CA) followed by flow cytometry analysis. The respect-
ive isotype control was also included. The flow cyto-
metry data was analyzed by CellQuest software (BD
Biosciences).
Gp120 binding assay
MT4 cells were incubated for 1 hour at 37°C with differing
concentrations of Slit2N After the incubation, cells were
washed with PBS and incubated with 1 μg/mL FITC-
conjugated recombinant gp120 (Immunodiagnostics,
Woburn, MA) for 30 minutes at room temperature. The
fluorescence intensity of gp120-FITC bound to the surface
of lymphocytes was measured with the FACS Calibur.
Virus binding assay
The procedure used to detect the binding of HIV-1 parti-
cles into target cells was described previously [54]. Briefly,
MT4 cells (1.0 × 106 cells/mL) were exposed to HIV-1
(40 ng p24) in the absence or presence of the Slit2N (3 and
6 nM) in 100 μL of PBS. After incubation at 4°C for 1 h,
unbound virus particles were removed by washing the cells
three times in PBS. Cell lysates were prepared by resus-
pending the pellet in lysis buffer (PBS containing 1% Triton
X). Viral binding was monitored by measuring the amount
of p24 in the cell lysates by ELISA. Total cell protein wascalculated using Bradford assay and all samples were nor-
malized for protein content.Viral entry assays
In the first method, MT4 cells (1.0 × 106 cells/mL) were
exposed to HIV-1 (40 ng p24) in the absence or presence
of the Slit2N (3nM and 6 nM) in 100 μL of PBS. After
incubation at 37°C for 4 hours, unbound virus particles
were removed by washing the cells three times in PBS.
The cells were treated with 0.05% trypsin for 10 min-
utes to remove surface-bound viral particles. Cell
lysates were prepared by resuspending the pellet in
lysis buffer (PBS containing 1% Triton X). Viral entry
was monitored by measuring the amount of p24 in the
cell lysates by ELISA. Total cell protein was calculated
using Bradford assay and all samples were normalized
for protein content.
In the second approach, viral entry was measured by the
virion-based fusion assay [36]. Briefly, a total of 1 x 106
MT4 cells were incubated 3 h with equivalent viral inputs
of BlaM-Vpr-containing virions (500 ng of p24) in 500 μl
RPMI 1640 medium. Cells were then extensively washed to
remove free virions and incubated (1 h, room temperature)
with CCF2-AM loading mix, as recommended by the
manufacturer (GeneBLAzer detection kit; Invitrogen).
Next, excess dye was washed off and cells were incubated
for 16 h at room temperature before fixation with 4% paraf-
ormaldehyde. Then, 8 × 105 cells were placed in a 96-well
plate per each experimental condition. The associated emis-
sion light to cleaved CCF2 (blue; 447 nm) and intact CCF2
probe (green; 520 nm) was measured. The entry of BlaM-
Vpr containing virions was measured as the ratio of the
maximum fluorescence intensity between cleaved and in-
tact CCF2. Thereby, an increase in this ratio indicates more
fused viruses with target cells. The percentage of infection
was determined by measuring the fluorescence intensities
of intact and cleaved CCF2 probe in control infected cells
(scrambled or pCDNA.3 transfected cells) and subtracting
the background blue and green fluorescence ratio deter-
mined in noninfected cells (without β-lactamase activity),
(GeneBLAzer detection kit; Invitrogen).Virus integration
Host cell nuclear integration of HIV in MT4 cells was
analyzed by PCR as described previously [55]. DNA
was prepared by using a DNA extraction kit (Qiagen,
Valencia, CA) according to the manufacturer’s proto-
col. DNA samples were used for the amplification of
integrated DNA with Alu-LTR–specific primers [37]
using the following cycling conditions: 95°C for 10
minutes, then 40 cycles at 95°C for 15 s, 60°C for 1 mi-
nute, and 72°C for 1 minute. GAPDH was used as an
internal control.
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multiple-spliced (MS) HIV-1 mRNA
RNA was prepared from untreated or Slit2N treated
HIV-1 IIIB-infected cells using the QIAamp RNAeasy
Mini Kit protocol (Qiagen). FL and MS HIV-1 mRNA
transcript levels were determined by a modification of a
protocol described [56]. qRT-PCR was performed using
primers (200nM) specific for FL and for MS using
400 ng of sample RNA in a SYBR Green assay system
using a Realplex Cycler (Eppendorf, Westbury, NY).
Transfections
SiRNA-mediated knockdown of Robo1 was performed
using specific ON-TARGETplus SMARTpool siRNA
(Dharmacon, Lafayette,CO). Briefly, MT4 cells were
nucleofected with 200 nM siRNA (Amaxa Biosystems).
The respective, non-targeted (NT) siRNA was used as a
control. Robo1 siRNA- -mediated knockdown was esti-
mated by detecting Robo1 expression 48 hours after the
initial transfection by Western blotting and/or flow
cytometry.
Rac1 activation assay
Rac1 activation was determined by using the Rac/Cdc42
activation assay kit (Millipore). In brief, cell lysates were
pre-cleared with sepharose beads were incubated with
20 μg/ml p21-activated kinase (PAK)-1 agarose for
60 minutes at 4°C, according to the manufacturer’s
instructions. Agarose beads were collected by centrifuga-
tion, followed by denaturation, boiling of the samples,
and SDS-PAGE analysis. Proteins were transferred to
nitrocellulose membranes, and Western blotting was
performed by using murine anti-human Rac1 antibody.
Blotting of equal amounts of lysates with total Rac1
represented the loading controls.
FITC-Phalloidin staining of F-actin
One to two million cells were stimulated with HIV-1
gp120 IIIB and incubated at 37°C with gentle agitation
(600 to 1200 rpm) to prevent cell settling at the bottom.
F-actin staining using FITC-labeled phalloidin (Sigma,
St. Louis, MO) was carried out according to the manu-
facturer’s recommendation with minor modifications.
Briefly, each staining was carried out using 1–2 × 106
cells. Cells were pelleted, fixed and permeabilized with
CytoPerm/Cytofix buffer (BD Biosciences) for 20 minutes
at room temperature, washed with cold Perm/Wash buf-
fer (BD Biosciences) twice, followed by staining with 5 μl
of 0.3 mM FITC-labeled phalloidin for 30 minutes on
ice in dark. After washing twice with cold Perm/Wash buf-
fer, cells were resuspended in 1% paraformaldehyde and
analyzed on a FACSCalibur (BD Biosciences). The cells
were also observed under a fluorescence microscope (ZeissAxiophot). Cells were scored as positive if increased F-actin
staining was observed.
Western blotting
Equivalent amounts of protein extracts were run on a
4% to 12% gradient acrylamide gel (NuPAGE Bis-Tris
gel; Invitrogen) and transferred onto nitrocellulose
membranes. Immunodetection involved specific primary
antibodies, appropriate secondary antibodies conjugated
to horseradish peroxidase, and the enhanced chemilu-
minescence Western blotting detection system (GE
Lifesciences).
Statistical analysis
Reported data are the means ± S.E.M. of at least three
independent experiments performed in duplicate or trip-
licate. The statistical significance was determined by the
Student’s t test.
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